DOSEGUY

Modafiendz

guinea pig

Also seen as: N-methyl-4,4-difluoromodafinil, N-methyl-4,4-difluoro-modafinil

The Dose Guy’s verdict
Sep 1, 2026
1 source

Modafiendz has no pharmacology data, no safety data, no human trial, and no animal study. The single paper in the literature is an analytical chemistry study about what happens when you heat it in a gas chromatograph. That is the entire published record. It’s sold as a modafinil upgrade, and the evidence behind that claim is nothing. If you want wakefulness, modafinil and adrafinil exist with actual data behind them. This one is a name on a label.

Would I take it?Not this one. Zero data when modafinil exists.

What it is

Modafiendz is N-methyl-4,4-difluoro-modafinil, a fluorinated, N-methylated tweak of modafinil sold through online research chemical shops. The assumption is that the fluorine atoms and the methyl group change absorption or potency, but no published study has tested whether modafiendz does anything in a living system, animal or human. The one indexed paper used it as a test analyte in a chromatography method study and found that heat in the injector port broke the molecule into unexpected fragments, which tells you something about analytical chemistry and nothing about your brain.

The modafinil-analog market runs on the bet that structural relatives share the parent’s pharmacology. Sometimes that holds. Sometimes it does not. Without a single receptor-binding, behavioral, or pharmacokinetic study, modafiendz is a structural bet with no data to back it.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The published record is one paper, and it is not about what modafiendz does to you:

The only indexed study identified modafiendz as N-methyl-4,4-difluoro-modafinil and documented that it degrades in a heated GC injection port, producing fluorinated artifacts that confuse standard analysis.Drug Test Anal 2017 · analytical chemistry
No human trial, no animal study, no pharmacokinetic measurement, no safety dataset, and no dose-response evidence for modafiendz appears in the PubMed corpus.as of Aug 2026

Realistic protocols

There is nothing to build a protocol from. No dose has been tested in any organism. The community doses modafiendz at roughly 50 to 200 mg orally, guessing from modafinil’s range, sometimes once in the morning for wakefulness. That is a guess based on structural similarity and nothing else. The honest question is why you would pick an untested analog over modafinil itself, or adrafinil, which at least converts to modafinil through a known pathway, liver tax and all. If you run it anyway, start low, run it alone, and do not assume the side-effect profile matches the parent compound.

Side effects

Nobody has measured a single side effect in any species:

unknownZero safety data. Not in people, not in animals, not in cells. You are the assay.
anecdotalForum users report a modafinil-like profile: wakefulness, reduced appetite, occasional headache. These are assumed from the structural relationship, not confirmed by any study.
unknownFluorinated drug analogs sometimes produce unexpected metabolites. No metabolism study exists for modafiendz, so what your liver turns it into is an open question.

Where to buy

No live listings from tracked vendors right now.